No description available.

Background/objectives There are few studies investigating the long-term association between childhood blood pressure (BP) and adult cardiovascular remodeling. We seek to examine the effect of elevated childhood BP on cardiovascular remodeling in early or middle adulthood.Methods We used the "Beijing BP Cohort Study", where 1259 subjects aged 6-18 years old were followed over 24 years from childhood (1987) to early or middle adulthood (2011). Anthropometric measures and BP were obtained at baseline and follow-up examinations. Carotid-femoral pulse wave velocity (cfPWV), carotid intima-media thickness (cIMT), and left ventricular mass index (LVMI) were measured to assess cardiovascular remodeling in early or middle adulthood. Multiple logistic regression models were used to assess the odds ratio (OR) and 95% confidence interval (CI) for cardiovascular remodeling.Results 82 out of 384 children with elevated BP (21.4%) had adult hypertension. Compared to those with normal BP, children with elevated BP were at 2.1 times (95% CI: 1.4-3.1) likely to develop hypertension in early or middle adulthood. Compared to those with normal BP, children with elevated BP were at higher OR of developing high cfPWV (OR = 1.8, 95% CI = 1.3-2.4), high cIMT (1.4, 1.0-1.9), or high LVMI (1.4, 1.0-1.9) in early or middle adulthood. The ORs for remodeling (for any measures) were 1.4 (0.9-2.0) in early adulthood for children age 6-11 years, and 1.6 (1.1-2.4) in middle adulthood for those aged 12-18 years.Conclusions Children with elevated BP from 6 years old have accelerated remodeling on both cardiac and arterial system in early or middle adulthood.

Abstract Left ventricular hypertrophy (LVH), a common complication of elevated blood pressure (BP), is a risk factor for cardiovascular (CV) morbidity and mortality. Adiponectin has been shown to have cardioprotective effects and is inversely associated with LVH. BP can be measured at a clinical visit, as a momentary value. Ambulatory blood pressure (APB) measurement (ABPM) is a method of repeated BP measurements through a defined period, targeted to evaluate the circadian BP profile. High BP and ABPM have been shown to be associated with LVH and left ventricular diastolic dysfunction (LVDD). A high sodium intake has been associated with elevated BP and adverse CV outcome. The aim of this study was to investigate the associations between adiponectin and left ventricular mass index (LVMI), a measure of LVH, ABPM and the development of LVDD during long-term follow-up, ABPM and the change in LVMI during long-term follow-up, and the role of dietary sodium intake in the incidence of AF. Adiponectin has been shown to have vasoprotective, anti-inflammatory and cardioprotective effects. Hypoadiponectinemia has been associated with hypertension, coronary artery disease (CAD) and LVH. In this study, adiponectin levels were inversely associated with LVMI, even after adjustment with conventional risk factors of LVH, in a fairly large sample of middle-aged subjects. Elevated BP and pulse pressure (PP) have been associated with echocardiographic measures of LVDD. In this study, the association between APBM and the development of LVDD during a 20-year follow-up was evaluated. Ambulatory PP (APP) was shown to independently associate with the development of LVDD, even after adjustment with conventional risk factors of LVDD. APBM has been associated with LVH in cross-sectional assessments and has also been shown to have predictive value in future LVMI or LVH. In a few studies the predictive value of APP in future LVMI was observed. In the present study, an increase in APP was shown to predict the change in LVMI during long-term follow-up. In this study, the association between dietary sodium intake and the incidence of AF was evaluated. A high sodium intake predicted the occurrence of AF, which is a novel finding. In conclusion, this study offers novel findings about predictive factors in the entity of cardiac remodelling. / Tiivistelmä Vasemman kammion hypertrofia on yleinen kohonneen verenpaineen seuraus ja sen on todettu olevan sydän- ja verisuonitapahtumien riskitekijä. Adiponektiinin on osoitettu suojaavan vasemman kammion hypertrofialta. Ambulatorinen verenpaineen mittaus on menetelmä, jossa verenpaine mitataan määritellyllä ajanjaksolla toistuvasti, mikä antaa kuvan verenpaineesta vuorokauden eri jaksoissa. Kohonneella ambulatorisella verenpaineella on osoitettu olevan yhteys vasemman kammion hypertrofiaan sekä vasemman kammion diastoliseen vajaatoimintaan. Runsas natriumin saanti on yhteydessä kohonneeseen verenpaineeseen sekä sydän- ja verisuonisairauksiin. Tämän tutkimuksen tarkoituksena on selvittää yhteyksiä adiponektiinin ja vasemman kammion massaindeksin välillä, ambulatorisen verenpaineen ja vasemman kammion diastolisen vajaatoiminnan kehittymisen välillä, ambulatorisen verenpaineen ja vasemman kammion massaindeksin muutoksen välillä sekä natriumin saannin ja eteisvärinän ilmaantuvuuden välillä. Adiponektiinilla on todettu olevan suotuisia vaikutuksia verisuonistoon, tulehdusreaktion hillintään sekä sydänlihakseen. Matalan adiponektiinitason on osoitettu olevan yhteydessä verenpainetautiin, sepelvaltimotautiin sekä vasemman kammion hypertrofiaan. Tässä tutkimuksessa adiponektiinihormonilla osoitettiin olevan käänteinen yhteys vasemman kammion massaindeksiin, vaikka perinteiset riskitekijät otettiin huomioon. Kohonneella verenpaineella sekä pulssipaineella on osoitettu olevan yhteys vasemman kammion diastoliseen vajaatoimintaan. Tässä tutkimuksessa arvioitiin ambulatorisen verenpaineen merkitystä vasemman kammion diastolisen vajaatoiminnan kehittymisessä. Ambulatorinen pulssipaine osoittautui riskitekijäksi, vaikka perinteiset riskitekijät otettiin huomioon. Ambulatorisella verenpaineella ja pulssipaineella on osoitettu olevan yhteys vasemman kammion hypertrofiaan poikkileikkaustutkimuksissa ja seurantatutkimuksissa. Tässä tutkimuksessa ambulatorisen pulssipaineen nousun havaittiin ennustavan vasemman kammion massaindeksin kasvua pitkäaikaisseurannassa. Tässä tutkimuksessa korkean natriumin saannin todettiin olevan yhteydessä lisääntyneeseen eteisvärinän ilmaantuvuuteen. Tätä yhteyttä ei ole aiemmin todettu muissa tutkimuksissa. Tässä tutkimuksessa löydettiin uusia riskitekijöitä sydämen patologisiin ilmentymiin liittyen.

Short summary: Background: High cardiovascular risk in patients with chronic kidney disease is partly due to mineral dysbalance, microinflammation and oxidative stress. CKD patients accumulate traditional and non-traditional CV risk factors. FGF23, MMPs and PlGF belong among these non-traditional biomarkers of CV risk. FGF23 is a phosphaturic hormone and inhibitor of calcitriol synthesis. It is associated with vascular calcifications. Matrix-metalloproteinases (e.g. MMP-2, MMP-9) are proteolytic, proinflammatory enzymes, contributing to myocardial remodelation. Placental growth factor (PlGF) is a proangiogenic cytokine that is associated with LV hypertrophy in animal model. Plasmatic FGF23, MMPs and PlGF are elevated in CKD. Aim: We aimed to describe dynamic changes between several novel biomarkers of CV risk (FGF23, MMP-2, MMP-9 and PlGF) in CKD stages 1-5, to describe their mutual correlations and possible association with traditional CV risk markers. We studied possible association of laboratory and echocardiographic parameters in patients with CKD stages 2-4. Methods: In a cross-sectional study we evaluated 80 patiens with CKD 1-5 and 44 healthy controls. In a prospective study we evaluated echocardiographic and laboratory parameters in 62 patients with CKD 2-4 for an average study period of 36±10...

Short summary: Background: High cardiovascular risk in patients with chronic kidney disease is partly due to mineral dysbalance, microinflammation and oxidative stress. CKD patients accumulate traditional and non-traditional CV risk factors. FGF23, MMPs and PlGF belong among these non-traditional biomarkers of CV risk. FGF23 is a phosphaturic hormone and inhibitor of calcitriol synthesis. It is associated with vascular calcifications. Matrix-metalloproteinases (e.g. MMP-2, MMP-9) are proteolytic, proinflammatory enzymes, contributing to myocardial remodelation. Placental growth factor (PlGF) is a proangiogenic cytokine that is associated with LV hypertrophy in animal model. Plasmatic FGF23, MMPs and PlGF are elevated in CKD. Aim: We aimed to describe dynamic changes between several novel biomarkers of CV risk (FGF23, MMP-2, MMP-9 and PlGF) in CKD stages 1-5, to describe their mutual correlations and possible association with traditional CV risk markers. We studied possible association of laboratory and echocardiographic parameters in patients with CKD stages 2-4. Methods: In a cross-sectional study we evaluated 80 patiens with CKD 1-5 and 44 healthy controls. In a prospective study we evaluated echocardiographic and laboratory parameters in 62 patients with CKD 2-4 for an average study period of 36±10...